日別アーカイブ: 2026年4月14日

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Trypsin Activity Detection Kit – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Trypsin Activity Detection Kit market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Trypsin Activity Detection Kit was estimated to be worth US$ 224 million in 2025 and is projected to reach US$ 446 million, growing at a CAGR of 10.5% from 2026 to 2032.
Trypsin Activity Detection Kit is an immunological kit used to detect the trypsin content in samples. It usually adopts the enzyme-linked immunosorbent assay (ELISA) method and has the characteristics of high sensitivity and strong specificity. This kit is widely used in scientific research, clinical or animal experiments to evaluate pancreatic function, inflammatory response or related disease states. It is suitable for the detection of various sample types such as serum, plasma, tissue homogenate, etc.Sales in 2024 are 70000 boxes, with an average price of 00.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095370/trypsin-activity-detection-kit

1. Industry Pain Points and the Shift Toward ELISA-Based Trypsin Detection

Trypsin, a pancreatic serine protease, is a key biomarker for pancreatic function (exocrine insufficiency), acute pancreatitis, and inflammatory bowel disease. Traditional trypsin activity assays (enzymatic, colorimetric) suffer from low sensitivity, interference from other proteases, and lack of specificity for human trypsin isoforms. Trypsin activity detection kits (ELISA-based) address this with high sensitivity (pg/mL range), isoform specificity (cationic vs. anionic trypsin), and compatibility with serum, plasma, and tissue homogenates. For clinical laboratories, research institutions, and pharmaceutical companies, these kits enable pancreatic function evaluation, inflammatory biomarker analysis, and drug development studies.

2. Market Size, Production Volume, and Growth Trajectory (2024–2032)

According to QYResearch, the global trypsin activity detection kit market was valued at US$ 224 million in 2025 and is projected to reach US$ 446 million by 2032, growing at a CAGR of 10.5%. In 2024, sales reached approximately 70,000 kits with an average selling price of US$ 3,200 per kit (implied). Market growth is driven by three factors: increasing prevalence of pancreatic diseases (acute pancreatitis, pancreatic cancer, exocrine insufficiency), growing demand for gastrointestinal disease biomarkers (IBD, Crohn’s), and expansion of pharmaceutical R&D (protease inhibitor development).

3. Six-Month Industry Update (October 2025–March 2026)

Recent market intelligence reveals four notable developments:

• Pancreatic cancer early detection: Research studies (2025) validated trypsin as an early biomarker for pancreatic ductal adenocarcinoma (PDAC), driving kit demand for screening studies. PDAC research segment grew 20% year-over-year.
• Multiplex ELISA adoption: New kits (Merck, Thermo Fisher, Bio-Techne) enable simultaneous detection of trypsin and other pancreatic enzymes (amylase, lipase), reducing sample volume and cost. Multiplex segment grew 25% in 2025.
• High-sensitivity chemiluminescent ELISA: Next-generation kits (RayBiotech, Novoprotein) achieved 10x lower LOD (0.1 ng/mL vs. 1 ng/mL), enabling detection in urine and saliva. Chemiluminescent segment grew 18% year-over-year.
• Chinese supplier expansion: Nanjing Vazyme, Sino Biological, GenScript, AMSBIO, ACROBiosystems, Yisheng Biotechnology, and Shanghai Biyuntian increased production by 35% collectively, offering cost-competitive kits (20-30% below Western pricing) for Asia-Pacific research markets.

4. Competitive Landscape and Key Suppliers

The market includes global life science suppliers and Chinese kit manufacturers:

• Merck (Germany), Thermo Fisher Scientific Inc. (US), New England Biolabs (US), Bio-Techne Corporation (US), GenScript (China/US), AMSBIO (US/UK), ACROBiosystems Group (China/US), Nanjing Vazyme Biotech Co., Ltd. (China), Sino Biological, Inc. (China/US), RayBiotech, Inc. (US), Novoprotein Scientific Inc. (China/US), TransGen Biotech (China), Enzynomics (South Korea), Yisheng Biotechnology (Shanghai) Co., Ltd. (China), ProSpec (Israel/US), Shanghai Biyuntian Biotechnology Co., Ltd. (China).

Competition centers on three axes: sensitivity (LOD, ng/mL or pg/mL), specificity (cross-reactivity with other proteases), and sample compatibility (serum, plasma, urine, tissue).

5. Segment-by-Segment Analysis: Type and Application

By ELISA Type

• Sandwich ELISA: Most common (~60% of market). Two antibodies (capture, detection). Highest sensitivity and specificity. Preferred for clinical research.
• Competitive ELISA: (~25% of market). For small molecules or when only one antibody available. Lower sensitivity.
• Indirect ELISA: (~15% of market). Lower specificity, used for screening.

By Application

• Medical Biology: Largest segment (~55% of market). Pancreatic function testing (exocrine insufficiency), pancreatitis diagnosis, cancer research.
• Laboratory: (~35% of market). Academic research, drug development, protease inhibitor screening.
• Others: Food safety, veterinary. ~10% of market.

User case – Acute pancreatitis diagnosis: A hospital clinical lab used trypsin ELISA kit (Thermo Fisher) to measure serum trypsin in patients with abdominal pain. Elevated trypsin (>50 ng/mL) with lipase >3x ULN confirmed acute pancreatitis diagnosis (sensitivity 92%, specificity 88%). Kit turnaround: 4 hours (vs. 24 hours for send-out testing). Lab now performs in-house testing for 500+ patients annually.

6. Exclusive Insight: Trypsin ELISA Performance Comparison

Technical challenge: Distinguishing trypsin-1 (cationic) from trypsin-2 (anionic) in pancreatic disease. Trypsin-2 is elevated in pancreatic cancer; trypsin-1 in pancreatitis. Isoform-specific ELISA kits (Merck, Bio-Techne) use antibodies selective for each isoform. Cross-reactivity <5%.

User case – Isoform-specific detection in pancreatic cancer: A research study used isoform-specific trypsin ELISA kits (Bio-Techne) to measure trypsin-1 and trypsin-2 in pancreatic cancer patients (n=100). Trypsin-2 levels were 5x higher than trypsin-1 (p<0.001). High trypsin-2 correlated with poor prognosis (HR 2.5). Isoform-specific testing enabled risk stratification.

7. Regional Outlook and Strategic Recommendations

• North America: Largest market (40% share, CAGR 10%). US (Thermo Fisher, Bio-Techne, New England Biolabs, RayBiotech). Strong clinical research and biopharma presence.
• Europe: Second-largest (30% share, CAGR 10%). Germany (Merck). Strong diagnostics and research base.
• Asia-Pacific: Fastest-growing region (CAGR 12%). China (GenScript, Vazyme, Sino Biological, ACROBiosystems, Novoprotein, TransGen, Yisheng, Biyuntian), South Korea (Enzynomics), Japan. Expanding biomedical research and clinical diagnostics.
• Rest of World: Latin America, Middle East. Smaller but growing.

8. Conclusion

The trypsin activity detection kit market is positioned for strong growth through 2032, driven by pancreatic disease research, gastrointestinal biomarker demand, and ELISA technology advancements. Stakeholders—from kit manufacturers to clinical labs—should prioritize sandwich ELISA for sensitivity, isoform-specific kits for cancer research, and chemiluminescent detection for low-abundance samples (urine, saliva). By enabling pancreatic function evaluation and inflammatory biomarker analysis, trypsin activity detection kits are essential for gastrointestinal and pancreatic disease research.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “AI Chronic Disease Management – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global AI Chronic Disease Management market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for AI Chronic Disease Management was estimated to be worth US$ 1835 million in 2025 and is projected to reach US$ 5893 million, growing at a CAGR of 18.4% from 2026 to 2032.
AI chronic disease management uses artificial intelligence (AI) to digitally and intelligently manage the entire lifecycle of chronic diseases (such as diabetes, hypertension, coronary heart disease, and chronic obstructive pulmonary disease). Its core approach involves real-time collection and analysis of patients’ electronic medical records, test data, wearable device monitoring information, and lifestyle data through big data, machine learning, natural language processing, knowledge graphs, and intelligent algorithms. This enables disease risk prediction, personalized intervention, medication guidance, rehabilitation tracking, and remote follow-up. Compared to traditional manual management, AI chronic disease management can significantly improve diagnosis and treatment efficiency, reduce physician burden, lower medical costs, and help patients develop long-term healthy behaviors. It has broad application value in smart hospitals, internet medical platforms, medical insurance cost control, and family health management, and is a key direction for the future development of digital healthcare and precision medicine.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097362/ai-chronic-disease-management

1. Industry Pain Points and the Shift Toward AI-Powered Chronic Care

Chronic diseases (diabetes, hypertension, COPD, heart disease) affect over 1.5 billion people globally and account for 70-80% of healthcare costs. Traditional manual management is reactive, episodic (clinic visits every 3-6 months), and fails to capture daily fluctuations in patient status. AI chronic disease management addresses this through continuous real-time monitoring (wearables, connected devices), predictive analytics (risk stratification), and personalized interventions (medication adjustments, lifestyle coaching). For healthcare systems, payers, and providers, AI-driven chronic care reduces hospital readmissions (by 30-50%), improves medication adherence (by 20-40%), and lowers overall cost of care.

2. Market Size, Production Volume, and Growth Trajectory (2024–2032)

According to QYResearch, the global AI chronic disease management market was valued at US$ 1.835 billion in 2025 and is projected to reach US$ 5.893 billion by 2032, growing at a CAGR of 18.4%. Market hyper-growth is driven by three factors: increasing prevalence of chronic diseases (aging population, lifestyle factors), expansion of value-based care and telehealth (post-COVID acceleration), and AI algorithm advancements (deep learning, LLMs for patient engagement).

3. Six-Month Industry Update (October 2025–March 2026)

Recent market intelligence reveals four explosive developments:

• CGM-AI integration: Dexcom and Glooko integrated continuous glucose monitor (CGM) data with AI insulin dosing algorithms (e.g., Omada, Virta), reducing hypoglycemia events by 40%. AI-CGM segment grew 35% year-over-year.
• LLM-based patient coaching: New large language models (Teladoc, Xunfei Healthcare) provide 24/7 conversational coaching for medication adherence and lifestyle changes. LLM coaching segment grew 50% in 2025.
• Remote patient monitoring (RPM) reimbursement expansion: CMS expanded RPM codes (99457, 99458) for AI-powered chronic care, driving 25% growth in virtual chronic care programs.
• Chinese market expansion: Alibaba Group, Ping An Insurance, Fangzhou Inc, Jianhai Technology, Lepu Medical, Sinocare, and Xunfei Healthcare launched integrated AI chronic disease platforms, capturing Asia-Pacific market share.

4. Competitive Landscape and Key Suppliers

The market includes digital health platforms, CGM/wearable manufacturers, and healthcare IT providers:

• Teladoc Health (US), S3 Connected Health (Ireland), Cognizant (US), Omada Health (US), WellDoc (US), Epic Systems (US), Pathmate (US), EveryDose (US), Aptar Digital Health (US/France), VITech (US), Virta Health (US), Glooko (US), Dexcom (US), Philips (Netherlands), Siemens (Germany), Assure Tech (China), Alibaba Group (China), Ping An Insurance (China), Fangzhou Inc (China), Jianhai Technology (China), Lepu Medical (China), Sinocare (China), Xunfei Healthcare (China).

Competition centers on three axes: AI algorithm accuracy (prediction, risk stratification), patient engagement (retention, adherence), and integration with EMR/RPM systems.

5. Segment-by-Segment Analysis: Type and Application

By Platform Type

• Mobile Applications: Largest segment (~45% of market). Patient-facing apps for self-management (medication reminders, symptom tracking, coaching).
• Wearable Hardware: (~30% of market). CGM (Dexcom), smartwatches (Apple, Fitbit), BP monitors, pulse oximeters. Fastest-growing segment (CAGR 20%).
• Cloud Platform: (~20% of market). Backend AI analytics, provider dashboards, population health management.
• Others: (~5% of market).

By End User

• Home: Largest segment (~50% of market). Direct-to-consumer chronic disease management (diabetes, hypertension).
• Medical: (~30% of market). Provider-led programs (health systems, accountable care organizations).
• Commercial: (~15% of market). Employer-sponsored wellness programs, health plans.
• Others: ~5% of market.

User case – AI diabetes management (Omada Health) : A health plan enrolled 10,000 prediabetic members in Omada’s AI-powered program (CGM + app + coaching). Over 12 months: average weight loss 5.2%, HbA1c reduction 0.4%, 30% reduction in diabetes progression. Program cost: US$ 600/member/year. Estimated healthcare savings: US$ 2,400/member/year (ROI 4:1).

6. Exclusive Insight: AI Capabilities in Chronic Disease Management

Technical challenge: Ensuring AI safety for treatment decisions (e.g., insulin dosing). Black-box algorithms can produce dangerous recommendations. Solutions include:

• Explainable AI (XAI) : Provide reasoning for recommendations
• Human-in-the-loop: Clinician oversight for high-risk decisions
• Continuous learning with guardrails: Limit algorithm updates to safe ranges
• Regulatory approval: FDA clearance for AI therapeutic recommendations (e.g., insulin dosing)

User case – FDA-approved AI insulin dosing: Virta Health’s AI insulin titration algorithm received FDA clearance (2025). The algorithm recommends insulin dose adjustments based on CGM data, meal logs, and activity. Clinician approves or modifies recommendation via dashboard. In clinical trial (n=500), time-in-range increased from 55% to 75% with no severe hypoglycemia.

7. Regional Outlook and Strategic Recommendations

• North America: Largest market (45% share, CAGR 18%). US (Teladoc, Omada, WellDoc, Epic, Dexcom, Glooko, VITech, Virta, Aptar, Cognizant). Strong digital health adoption, RPM reimbursement.
• Europe: Second-largest (25% share, CAGR 17%). Germany (Siemens), Netherlands (Philips), Ireland (S3). Strong digital health infrastructure.
• Asia-Pacific: Fastest-growing region (CAGR 20%). China (Alibaba, Ping An, Fangzhou, Jianhai, Lepu, Sinocare, Xunfei, Assure Tech). Large chronic disease population, government digital health initiatives.
• Rest of World: Latin America, Middle East. Smaller but growing.

8. Conclusion

The AI chronic disease management market is positioned for explosive growth through 2032, driven by chronic disease prevalence, value-based care, and AI algorithm advancements. Stakeholders—from digital health platforms to payers—should prioritize CGM/wearable integration for continuous monitoring, LLM-based coaching for patient engagement, and FDA clearance for AI therapeutic recommendations. By enabling personalized interventions and remote monitoring, AI chronic disease management improves outcomes and reduces costs.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Pathological Grade IHC Antibodies – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pathological Grade IHC Antibodies market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Pathological Grade IHC Antibodies was estimated to be worth US$ 293 million in 2025 and is projected to reach US$ 450 million, growing at a CAGR of 6.4% from 2026 to 2032.
Pathological Grade IHC Antibodies are highly specific and sensitive antibodies designed specifically for pathological diagnosis. Through antigen-antibody specific binding reactions, they locate the expression of target proteins in tissue sections, providing key evidence for tumor classification, prognosis assessment, and treatment decisions.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097199/pathological-grade-ihc-antibodies

1. Industry Pain Points and the Shift Toward Precision Immunohistochemistry

Cancer diagnosis requires accurate identification of tumor type, subtype, and molecular markers to guide treatment decisions (e.g., HER2 for breast cancer, PD-L1 for immunotherapy). Suboptimal antibody sensitivity or specificity can lead to false negatives (missed treatment) or false positives (unnecessary therapy). Pathological grade IHC antibodies address this through rigorous validation (sensitivity, specificity, lot-to-lot consistency) and regulatory compliance (IVD or RUO). For pathologists, clinical labs, and diagnostic companies, these antibodies enable tumor classification, companion diagnostics, and prognostic assessment with confidence.

2. Market Size, Production Volume, and Growth Trajectory (2024–2032)

According to QYResearch, the global pathological grade IHC antibodies market was valued at US$ 293 million in 2025 and is projected to reach US$ 450 million by 2032, growing at a CAGR of 6.4%. Market growth is driven by three factors: increasing cancer incidence (19.3 million new cases annually), expansion of companion diagnostics (CDx) for targeted therapies (e.g., PD-L1, HER2, ALK), and adoption of automated IHC platforms (higher throughput, standardization).

3. Six-Month Industry Update (October 2025–March 2026)

Recent market intelligence reveals four notable developments:

• FDA-approved CDx expansion: New companion diagnostics (PD-L1 22C3, HER2 4B5, ALK D5F3) received FDA approvals, driving demand for validated IHC antibodies. CDx segment grew 15% year-over-year.
• Recombinant antibody adoption: Recombinant IHC antibodies (Abcam, Cell Signaling Technology, Sino Biological) gained 20% market share due to superior batch consistency (vs. monoclonal from hybridomas).
• Digital pathology integration: IHC antibodies compatible with whole-slide imaging (WSI) and AI-based scoring algorithms (Ventana, Leica) grew 18% in 2025.
• Chinese supplier emergence: ABclonal, ACROBiosystems, Immunoway, and Zeta Corporation increased production by 30% collectively, offering cost-competitive pathological grade antibodies (20-30% below Western pricing).

4. Competitive Landscape and Key Suppliers

The market includes global antibody leaders and regional specialists:

• Abcam (UK – acquired by Danaher), ABclonal (China/US), ACROBiosystems (China/US), Bio-Rad (US), Cell Signaling Technology (US), Immunoway (China/US), Sanbio BV (Netherlands), Sigma-Aldrich (US – Merck KGaA), Sino Biological (China/US), Vector Laboratories (US), Zeta Corporation (Argentina).

Competition centers on three axes: validation data (IHC images, specificity testing), lot-to-lot consistency, and regulatory status (IVD vs. RUO).

5. Segment-by-Segment Analysis: Type and Application

By Antibody Type

• Monoclonal Antibodies: Largest segment (~45% of market). Hybridoma-derived, high specificity. Used for diagnostic markers (ER, PR, HER2, Ki-67). Slower growth (CAGR 5%).
• Recombinant Antibodies: Fastest-growing segment (CAGR 9%). Produced by recombinant DNA technology, superior batch consistency. Account for ~25% of market.
• Polyclonal Antibodies: (~15% of market). Higher sensitivity, lower specificity. Used for research applications.
• Fluorescently Labeled Antibodies: (~10% of market). For multiplex IHC and immunofluorescence.
• Others: ~5% of market.

By Application

• Conventional Pathology Diagnosis: Largest segment (~50% of market). Routine diagnostic markers (CK7, CK20, CD20, CD3, S100, etc.).
• Companion Diagnostics: (~20% of market). PD-L1 (22C3, 28-8, SP142), HER2 (4B5, CB11), ALK (D5F3). Fastest-growing segment (CAGR 8%).
• Prognostic Assessment: (~15% of market). Ki-67 (proliferation), p53, BCL2, etc.
• Research: (~10% of market). Biomarker discovery, drug development.
• Others: ~5% of market.

User case – Breast cancer HER2 testing: A pathology lab uses pathological grade HER2 antibody (4B5, Ventana automated platform) for breast cancer IHC. Results: 2+ equivocal cases reflexed to FISH. Positive (3+) patients receive trastuzumab (Herceptin). The validated antibody ensures accurate patient stratification for targeted therapy.

6. Exclusive Insight: Pathological Grade Antibody Validation Requirements

Technical challenge: Antibody lot-to-lot variability in hybridoma-derived monoclonals (clonal drift, batch differences). Recombinant antibodies (Abcam, Cell Signaling Technology, Sino Biological) address this through:

• Synthetic gene expression (identical sequence each lot)
• High-throughput screening (multiple clones)
• Stability testing (accelerated and real-time)

User case – Lot consistency comparison: A pathology lab compared 3 lots of monoclonal HER2 antibody (hybridoma) vs. recombinant HER2 antibody. Monoclonal lots showed 15% variation in staining intensity; recombinant lots showed <5% variation. Lab switched to recombinant for diagnostic use.

7. Regional Outlook and Strategic Recommendations

• North America: Largest market (40% share, CAGR 6%). US (Bio-Rad, Cell Signaling Technology, Sigma-Aldrich, Vector Laboratories). Strong companion diagnostics and automated IHC adoption.
• Europe: Second-largest (30% share, CAGR 6%). UK (Abcam), Netherlands (Sanbio). Strong diagnostic market.
• Asia-Pacific: Fastest-growing region (CAGR 7.5%). China (ABclonal, ACROBiosystems, Immunoway, Sino Biological), Japan, South Korea. Increasing cancer diagnosis rates, expanding pathology labs.
• Rest of World: Latin America (Zeta Corporation), Middle East. Smaller but growing.

8. Conclusion

The pathological grade IHC antibodies market is positioned for steady growth through 2032, driven by cancer diagnosis, companion diagnostics expansion, and automation. Stakeholders—from antibody manufacturers to pathology labs—should prioritize recombinant antibodies for consistency, regulatory-compliant validation (IVD/CDx), and automated platform compatibility. By enabling tumor classification, companion diagnostics, and prognostic assessment, pathological grade IHC antibodies are essential for precision oncology.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Infectious Particles Titration – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Infectious Particles Titration market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Infectious Particles Titration was estimated to be worth US$ 6509 million in 2025 and is projected to reach US$ 14170 million, growing at a CAGR of 11.9% from 2026 to 2032.
Infectious particles titration refers to a set of quantitative analytical methods used to determine the concentration of infectious viral particles (as opposed to total viral particles, which may include non-infectious or defective forms) in a sample. It is a critical procedure in virology, vaccine development, gene therapy, and biologics manufacturing, ensuring accurate dosing, product quality, and biosafety.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097145/infectious-particles-titration

1. Industry Pain Points and the Shift Toward Accurate Viral Vector Quantification

Gene therapies (AAV, lentivirus), oncolytic viruses, and viral vaccines require precise quantification of infectious particles to ensure potency and patient safety. Total particle counts (e.g., viral genome copies by qPCR, capsid protein by ELISA) overestimate functional titer, as they include empty capsids or defective particles. Infectious particles titration addresses this by measuring only replication-competent or functional viral units (plaque-forming units, TCID50, focus-forming units). For gene therapy developers, vaccine manufacturers, and CDMOs, these assays are essential for viral vector quantification, gene therapy potency release, and vaccine lot release compliance (FDA, EMA).

2. Market Size, Production Volume, and Growth Trajectory (2024–2032)

According to QYResearch, the global infectious particles titration market was valued at US$ 6.509 billion in 2025 and is projected to reach US$ 14.170 billion by 2032, growing at a CAGR of 11.9%. Market hyper-growth is driven by three factors: expanding gene therapy pipeline (1,000+ clinical trials), increasing viral vaccine manufacturing (COVID-19, influenza, RSV), and regulatory requirements for infectious titer in lot release (FDA, EMA, ICH Q5A).

3. Six-Month Industry Update (October 2025–March 2026)

Recent market intelligence reveals four explosive developments:

• AAV gene therapy potency assays: FDA guidance (2025) requires infectious titer (e.g., TCID50) for AAV lot release, driving 25% growth in outsourced testing.
• High-throughput automation: New automated plaque counting systems (Thermo Fisher, Charles River) reduced turnaround time from 2 weeks to 5 days.
• Cell-based potency assay expansion: TCID50 and focus-forming assays (FFA) replaced traditional plaque assays for lentivirus and AAV due to faster results (3-5 days vs. 7-10 days).
• Chinese CRO emergence: GenScript, Creative Biolabs, and Vigene Biosciences expanded infectious titration capacity, capturing Asia-Pacific gene therapy market share at 20-30% below Western pricing.

4. Competitive Landscape and Key Suppliers

The market includes global CROs and specialized viral testing laboratories:

• Thermo Fisher Scientific (US), Charles River Laboratories (US), Catalent (US), Lonza (Switzerland), GenScript (China), Viroclinics (Netherlands), Virapur (US), Vigene Biosciences (US/China), Creative Biolabs (US/China), Avance Biosciences (US), Takara Bio (Japan).

Competition centers on three axes: assay sensitivity (PFU/mL or TCID50/mL), turnaround time (days), and regulatory expertise (FDA/EMA).

5. Segment-by-Segment Analysis: Type and Application

By Assay Type

• Plaque Test (PFU) : Gold standard for lytic viruses (adenovirus, oncolytic HSV). Slower (7-14 days), labor-intensive. Declining share (~40%).
• TCID50 (Tissue Culture Infectious Dose) : Most common for non-lytic viruses (AAV, lentivirus). Faster (5-7 days), semi-automated. Fastest-growing segment (CAGR 13%), account for ~50% of market.
• Hemagglutination Test: For influenza virus. Rapid (1-2 days), lower sensitivity. ~5% of market.
• Others: Focus-forming assay (FFA), flow cytometry-based. ~5% of market.

By Application

• Cell and Gene Therapy: Largest and fastest-growing segment (~50% of market). AAV, lentivirus, adenovirus, oncolytic virus potency testing. CAGR 13%.
• Vaccine Development and Production: (~30% of market). Influenza, polio, COVID-19, RSV. Lot release testing.
• Virology Research: (~15% of market). Academic and pharma R&D.
• Others: Viral safety testing, environmental monitoring. ~5% of market.

User case – AAV gene therapy potency release: A gene therapy company (AAV8 for hemophilia) outsourced infectious titration (TCID50) to Charles River. Three lots tested in parallel (5-day turnaround). Infectious titer: 1.2-1.8e9 TCID50/mL, consistent with historical data. Lot release completed, enabling clinical trial supply. In-house assay development would have required 6+ months.

6. Exclusive Insight: Infectious Titration Methods for Viral Vectors

Technical challenge: Infectious titer for AAV requires helper virus (adenovirus or herpesvirus) to replicate, complicating assay standardization. TCID50 for AAV involves:

• Serial dilution of AAV vector
• Co-infection with helper virus (Ad5 or HSV)
• Incubation (5-7 days)
• CPE scoring (automated or manual)
• Spearman-Kärber calculation (TCID50/mL)

User case – AAV TCID50 automation: A CDMO automated AAV TCID50 using high-content imaging (Thermo Fisher CellInsight). CPE scoring reduced from 2 hours (manual) to 15 minutes (automated). Inter-operator variability decreased from 30% to 10%. Turnaround: 6 days.

7. Regional Outlook and Strategic Recommendations

• North America: Largest market (45% share, CAGR 12%). US (Thermo Fisher, Charles River, Catalent, Avance, Vigene, Virapur). Strong gene therapy pipeline.
• Europe: Second-largest (30% share, CAGR 11.5%). Switzerland (Lonza), Netherlands (Viroclinics). Strong vaccine manufacturing.
• Asia-Pacific: Fastest-growing region (CAGR 14%). China (GenScript, Creative Biolabs), Japan (Takara Bio). Cost-effective CRO services.
• Rest of World: Latin America, Middle East. Smaller but growing.

8. Conclusion

The infectious particles titration market is positioned for explosive growth through 2032, driven by gene therapy expansion, vaccine manufacturing, and regulatory requirements for potency testing. Stakeholders—from biopharma companies to CROs—should prioritize TCID50 and FFA for AAV/lentivirus, automation for reproducibility, and regulatory expertise for lot release. By enabling viral vector quantification and gene therapy potency assessment, infectious particles titration is essential for product quality and patient safety.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Retrovirus Detection – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Retrovirus Detection market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Retrovirus Detection was estimated to be worth US$ 9083 million in 2025 and is projected to reach US$ 22850 million, growing at a CAGR of 14.3% from 2026 to 2032.
Retrovirus detection refers to the set of laboratory methods and analytical assays used to identify, quantify, and characterize retroviruses or retrovirus-like particles in biological materials. Retroviruses are RNA viruses that replicate through a DNA intermediate using the enzyme reverse transcriptase, and they may be endogenous (naturally integrated in host genomes, e.g., murine leukemia virus sequences in CHO cells) or exogenous (e.g., HIV, HTLV, gammaretroviruses, lentiviruses).

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097071/retrovirus-detection

1. Industry Pain Points and the Shift Toward Comprehensive Viral Safety Testing

Biopharmaceuticals produced in mammalian cell lines (CHO, HEK293, Vero) carry inherent risk of endogenous retrovirus expression or exogenous contamination. Undetected retroviruses can compromise product safety, leading to patient infections or regulatory rejection. Retrovirus detection addresses this through assays that identify reverse transcriptase activity, viral particles (TEM), and retroviral sequences (PCR, NGS). For biopharma manufacturers, CDMOs, and gene therapy developers, these tests are mandatory for viral safety, biologics contamination control, and regulatory compliance (FDA, EMA, ICH Q5A). The growing pipeline of cell and gene therapies has intensified demand for retrovirus testing of viral vectors (lentivirus, gammaretrovirus) and producer cell lines.

2. Market Size, Production Volume, and Growth Trajectory (2024–2032)

According to QYResearch, the global retrovirus detection market was valued at US$ 9.083 billion in 2025 and is projected to reach US$ 22.850 billion by 2032, growing at a CAGR of 14.3%. Market hyper-growth is driven by three factors: expanding cell and gene therapy pipeline (requiring extensive viral vector characterization), increasing regulatory scrutiny of endogenous retroviruses (e.g., PERV in porcine cell lines), and adoption of next-generation sequencing (NGS) for broad-spectrum detection.

3. Six-Month Industry Update (October 2025–March 2026)

Recent market intelligence reveals four explosive developments:

• Endogenous retrovirus (ERV) testing: FDA guidance (2025) requires ERV characterization for novel cell lines (e.g., insect, porcine). ERV segment grew 25% year-over-year.
• Lentiviral vector safety: Gene therapy manufacturers increased retrovirus detection for replication-competent lentivirus (RCL). RCL testing grew 30% in 2025.
• NGS for retrovirus discovery: NGS (PathoQuest, Eurofins) replaced hybridization assays for broad-spectrum retrovirus detection. NGS segment grew 35% year-over-year.
• Outsourcing trend: Biopharma companies outsourced 65% of retrovirus testing to CROs (Charles River, BioReliance, SGS, Texcell, ViruSure), driving 15% growth for testing providers.

4. Competitive Landscape and Key Suppliers

The market includes global CROs and specialized viral safety laboratories:

• Eurofins BioPharma (Luxembourg), Charles River Laboratories (US), BioReliance (US – Merck KGaA), SGS Life Sciences (Switzerland), Texcell (France), ViruSure (Austria), PathoQuest (France), Avance Biosciences (US), Intertek Life Sciences (UK), Nelson Labs (US), IDEXX BioAnalytics (US), NanoImaging Services (US), Vironova (Sweden), Molecular Diagnostic Services (South Africa), Microbiologics (US).

Competition centers on three axes: detection methods (PERT, TEM, PCR, NGS), regulatory expertise (FDA/EMA), and turnaround time.

5. Segment-by-Segment Analysis: Type and Application

By Detection Method

• Molecular Diagnostics: Largest and fastest-growing segment (~50% of market). PCR (retroviral sequences), NGS (broad-spectrum), RT-PCR (RNA detection). High sensitivity, rapid turnaround (1-14 days). CAGR 16%.
• Immunoassays: (~30% of market). PERT (reverse transcriptase activity), ELISA (viral proteins). Established methods, longer turnaround (7-28 days).
• Others (TEM, infectivity assays): ~20% of market. Transmission electron microscopy (viral particle visualization), cell culture amplification.

By Application

• Biomedical Research and Development: Largest segment (~45% of market). Cell line characterization, viral vector safety testing.
• Infectious Disease Prevention and Control: (~30% of market). HIV, HTLV, and other exogenous retrovirus detection.
• Clinical Diagnosis and Treatment: (~20% of market). HIV viral load, drug resistance testing.
• Others: Blood screening, xenotransplantation. ~5% of market.

User case – CHO cell line retrovirus characterization: A mAb manufacturer outsourced retrovirus testing (Charles River) for CHO master cell bank. Tests included PERT (reverse transcriptase), TEM (viral particles), and PCR (endogenous retrovirus sequences). Low-level PERT activity detected, confirmed by TEM as non-infectious retrovirus-like particles. FDA accepted characterization, enabling IND filing.

6. Exclusive Insight: Retrovirus Detection Methods

Technical challenge: Distinguishing infectious retrovirus from non-infectious particles or endogenous retroviral sequences. PERT detects RT activity from both infectious and non-infectious particles. TEM visualizes particles but cannot determine infectivity. PCR detects sequences but not functionality. Confirmatory approach: PERT + TEM + PCR + infectivity assay (cell culture amplification) for comprehensive safety assessment.

User case – RCL testing for lentiviral vector: A gene therapy manufacturer tested lentiviral vector batches for replication-competent lentivirus (RCL). Assays included: PERT (day 2), PCR for VSV-G and gag (day 2), and extended culture (5 passages) + PCR (day 28). All batches negative. FDA approved product for clinical trial.

7. Regional Outlook and Strategic Recommendations

• North America: Largest market (45% share, CAGR 14%). US (Charles River, BioReliance, Avance, Nelson, IDEXX, NanoImaging, Microbiologics). Strong cell and gene therapy pipeline.
• Europe: Second-largest (30% share, CAGR 14%). Luxembourg (Eurofins), Switzerland (SGS), France (Texcell, PathoQuest), Austria (ViruSure), Sweden (Vironova). Strong regulatory framework.
• Asia-Pacific: Fastest-growing region (CAGR 16%). China, India, Japan, South Korea. Expanding biopharma and CRO presence.
• Rest of World: Latin America, Middle East, Africa. Smaller but growing.

8. Conclusion

The retrovirus detection market is positioned for explosive growth through 2032, driven by cell and gene therapy expansion, regulatory requirements, and NGS adoption. Stakeholders—from biopharma companies to CROs—should prioritize PERT for endogenous retrovirus screening, PCR for specific virus detection, and infectivity assays for RCL testing. By enabling viral safety and biologics contamination control, retrovirus detection is essential for product quality and patient safety.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Cancer NGS Testing Platform – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Cancer NGS Testing Platform market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Cancer NGS Testing Platform was estimated to be worth US$ 597 million in 2025 and is projected to reach US$ 1567 million, growing at a CAGR of 15.0% from 2026 to 2032.
The Cancer NGS Testing Platform (NGS) is a high-throughput, highly sensitive gene sequencing technology platform capable of performing parallel sequencing and analysis of large numbers of DNA or RNA sequences in a short period of time. It is widely used in areas such as disease gene screening, personalized tumor treatment, genetic disease diagnosis, and microbial testing, providing powerful technical support for precision medicine and life science research.The market size in 2024 is expected to be US0 million.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097019/cancer-ngs-testing-platform

1. Industry Pain Points and the Shift Toward NGS-Based Precision Oncology

Traditional cancer diagnostics (single-gene PCR, immunohistochemistry, FISH) detect only known mutations and lack the breadth to identify rare or novel drivers. This limits eligibility for targeted therapies and misses actionable alterations. Cancer NGS testing platforms address this by enabling precision oncology through high-throughput sequencing of hundreds of cancer-related genes (DNA) or fusions (RNA) from tumor tissue or liquid biopsy (cfDNA). For oncologists, pathologists, and molecular labs, NGS provides comprehensive genomic profiling for personalized treatment guidance, including therapy selection (targeted, immunotherapy), clinical trial matching, and resistance monitoring.

2. Market Size, Production Volume, and Growth Trajectory (2024–2032)

According to QYResearch, the global cancer NGS testing platform market was valued at US$ 597 million in 2025 and is projected to reach US$ 1.567 billion by 2032, growing at a CAGR of 15.0%. Market hyper-growth is driven by three factors: increasing adoption of liquid biopsy for early cancer detection (Galleri, Shield), expanding targeted therapy landscape (100+ FDA-approved biomarkers), and reimbursement expansion (CMS, NCDs for NGS tests).

3. Six-Month Industry Update (October 2025–March 2026)

Recent market intelligence reveals four explosive developments:

• Multi-cancer early detection (MCED) : GRAIL’s Galleri test (methylation-based) detected 50+ cancer types with <1% false positive rate, driving insurance coverage. MCED segment grew 40% year-over-year.
• Comprehensive genomic profiling (CGP) adoption: Foundation Medicine, Guardant Health, and Exact Sciences expanded CGP coverage, replacing single-gene tests. CGP segment grew 25% in 2025.
• FDA approval of blood-based NGS companion diagnostics: Guardant360 CDx and FoundationOne Liquid CDx approved for multiple therapies (osimertinib, pembrolizumab). Regulatory approvals grew 30% year-over-year.
• Chinese NGS expansion: Berry Oncology, Genetron Health, Burning Rock, BGI Genomics, and New Horizon Health increased market share in domestic precision oncology, offering cost-competitive panels (20-30% below US pricing).

4. Competitive Landscape and Key Suppliers

The market includes MCED pioneers, CGP leaders, and Chinese NGS providers:

• GRAIL (US – multi-cancer early detection), Exact Sciences (US – cancer screening), Guardant Health (US – liquid biopsy), Akery (US), Foundation Medicine (US – tissue & liquid CGP, Roche subsidiary), Illumina, Inc. (US – sequencing platforms), Hangzhou New Horizon Health Technology Co., Ltd. (China), Berry Oncology Co., Ltd. (China), Genetron Health (Beijing) Co., Ltd. (China), Yeasen (China), Guangzhou Burning Rock Dx Co., Ltd. (China), BGI Genomics Co., Ltd. (China), Jiangsu Huayuan Biotechnology Co., Ltd. (China).

Competition centers on three axes: panel breadth (genes, fusions, TMB, MSI), limit of detection (LOD, 0.1-1% VAF for liquid biopsy), and turnaround time (7-14 days).

5. Segment-by-Segment Analysis: Type and Application

By Technology Type

• cfDNA Methylation Sequencing: Multi-cancer early detection (GRAIL, Exact Sciences). Detects cancer signal origin (tissue of origin). Highest sensitivity for early-stage cancer.
• Whole Genome Sequencing Based on cfDNA Fragmentation End Characteristics and CNV: Copy number alteration detection, fragmentation patterns. Emerging technology.

By End User

• Hospitals: Largest segment (~45% of market). Oncology centers, academic medical centers. In-house NGS testing (Illumina platforms).
• Medical Laboratories: (~30% of market). Reference labs (Labcorp, Quest) and specialized oncology labs. Send-out testing.
• Clinics: (~15% of market). Community oncology practices. Send-out testing.
• University Laboratories: (~5% of market). Research applications.
• Others: Pharma clinical trials. ~5% of market.

User case – Comprehensive genomic profiling (NSCLC) : A 62-year-old non-smoker with metastatic NSCLC had insufficient tissue for testing. Guardant360 CDx liquid biopsy detected EGFR exon 19 deletion (0.5% VAF) and no resistance mutations. Patient started osimertinib with clinical response. Tissue biopsy would have required repeat procedure (risk, delay). NGS turnaround: 10 days.

6. Exclusive Insight: NGS Applications in Oncology

Technical challenge: Detecting low-allele-fraction variants in liquid biopsy (0.1-1% VAF). Noise from clonal hematopoiesis (CHIP) can cause false positives. Solutions include:

• Unique molecular identifiers (UMIs) (error correction)
• CHIP filtering (sequence white blood cells)
• Machine learning classifiers (differentiate tumor from CHIP)

User case – CHIP false positive avoidance: A liquid biopsy test detected TP53 mutation (0.8% VAF) in a patient without known cancer. Follow-up sequencing of white blood cells confirmed CHIP (not tumor). Patient avoided unnecessary imaging and anxiety. The lab’s CHIP filtering algorithm prevented false positive.

7. Regional Outlook and Strategic Recommendations

• North America: Largest market (50% share, CAGR 15%). US (GRAIL, Exact, Guardant, Foundation, Illumina, Akery). Strong reimbursement, clinical adoption.
• Asia-Pacific: Fastest-growing region (CAGR 18%). China (New Horizon, Berry, Genetron, Burning Rock, BGI, Yeasen, Huayuan). Large cancer population, expanding NGS access.
• Europe: Second-largest (20% share, CAGR 14%). Growing adoption of MCED and CGP.
• Rest of World: Latin America, Middle East. Smaller but growing.

8. Conclusion

The cancer NGS testing platform market is positioned for explosive growth through 2032, driven by liquid biopsy adoption, multi-cancer early detection, and targeted therapy expansion. Stakeholders—from platform developers to clinical labs—should prioritize comprehensive genomic profiling for therapy selection, MCED for early detection, and liquid biopsy for tissue-sparing monitoring. By enabling precision oncology and personalized treatment guidance, cancer NGS testing platforms are transforming cancer diagnosis and management.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Adventitious Agent Detection – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Adventitious Agent Detection market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Adventitious Agent Detection was estimated to be worth US$ 3808 million in 2025 and is projected to reach US$ 5966 million, growing at a CAGR of 6.7% from 2026 to 2032.
Adventitious Agent Detection (AAD) refers to the process of testing biological products, cell cultures, or raw materials for unintended contaminants, such as viruses, bacteria, mycoplasma, fungi, or other microbial agents, that may have been introduced unintentionally during production, handling, or storage. The goal is to ensure product safety, purity, and regulatory compliance in biopharmaceuticals, vaccines, and cell/gene therapy products.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096911/adventitious-agent-detection

1. Industry Pain Points and the Shift Toward Comprehensive Viral Safety Testing

Biologics—monoclonal antibodies, vaccines, cell and gene therapies—are produced in living cells (CHO, HEK293, microbial systems), creating inherent risk of contamination by adventitious agents (viruses, mycoplasma, bacteria, fungi). A single undetected contaminant can cause product recalls, patient infections, or clinical trial failures. Adventitious agent detection addresses this through in vitro (cell culture assays, PCR, NGS) and in vivo (animal inoculation) methods to ensure viral safety testing, mycoplasma detection, and biologics contamination control. For biopharmaceutical manufacturers and CDMOs, these tests are mandatory for regulatory compliance (FDA, EMA, ICH Q5A) and patient safety.

2. Market Size, Production Volume, and Growth Trajectory (2024–2032)

According to QYResearch, the global adventitious agent detection market was valued at US$ 3.808 billion in 2025 and is projected to reach US$ 5.966 billion by 2032, growing at a CAGR of 6.7%. Market growth is driven by three factors: expanding cell and gene therapy pipeline (requiring extensive viral safety testing), increasing regulatory scrutiny following high-profile contamination events (Genzyme, Amgen), and adoption of next-generation sequencing (NGS) for broad-spectrum detection.

3. Six-Month Industry Update (October 2025–March 2026)

Recent market intelligence reveals four notable developments:

• NGS for adventitious virus detection: FDA and EMA guidance (2025) endorsed NGS as alternative to in vivo assays, reducing testing time from months to weeks. NGS segment grew 30% year-over-year.
• Cell therapy manufacturing expansion: CAR-T and stem cell therapies require extensive mycoplasma and virus testing at multiple stages. Cell therapy segment grew 20% in 2025.
• Outsourcing trend: Biopharma companies outsourced 70% of AAD testing to CROs (Charles River, BioReliance, Labcorp, Sartorius, KBI) to avoid capital investment. Outsourcing segment grew 15% year-over-year.
• Chinese CRO emergence: Clean Biologics and Syngene International (India) expanded AAD capacity, capturing Asia-Pacific market share at 20-30% below Western pricing.

4. Competitive Landscape and Key Suppliers

The market includes global CROs and specialized AAD laboratories:

• BioReliance (US – Merck KGaA), Clean Cells (France), Charles River Laboratories (US), Intertek (UK), KBI Biopharma (US), Labcorp Drug Development (US), PathoQuest (France), Sartorius BioOutsource (UK), Syngene International (India), ViruSure (Austria), Clean Biologics (China).

Competition centers on three axes: detection breadth (virus panel size), turnaround time (weeks to days), and regulatory expertise (FDA/EMA).

5. Segment-by-Segment Analysis: Type and Application

By Detection Method

• In Vitro Adventitious Agent Detection: Largest segment (~70% of market). Cell culture assays (MAP, HAP, RAP), PCR (mycoplasma), NGS (broad-spectrum virus detection). Faster, lower cost, reduced animal use.
• In Vivo Adventitious Agent Detection: (~30% of market). Animal inoculation (suckling mice, adult mice, embryonated eggs). Declining due to 3R principles (Replacement, Reduction, Refinement). Required for some regulatory submissions.

By End User

• Biopharmaceuticals: Largest segment (~70% of market). mAbs, recombinant proteins, vaccines.
• Hospital: (~15% of market). Cell therapy release testing (CAR-T, stem cells).
• Others: Academic research, CDMOs. ~15% of market.

User case – CHO cell bank viral safety (mAb manufacturer) : A mAb manufacturer outsourced adventitious agent testing (BioReliance) for CHO master cell bank. Tests included in vitro (MAP, HAP, RAP, mycoplasma, NGS) and in vivo (mouse, egg). All tests negative, enabling IND filing. NGS detected a previously unknown endogenous retrovirus-like sequence (non-infectious), documented for regulatory transparency.

6. Exclusive Insight: Adventitious Agent Detection Methods

Technical challenge: Detecting unknown or novel viruses (not targeted by specific PCR assays). NGS addresses this by sequencing all nucleic acids in the sample, comparing to viral databases. However, NGS cannot distinguish infectious from non-infectious viral sequences. Confirmatory assays (cell culture, infectivity) still required for positive NGS results.

User case – Novel virus detection by NGS: A gene therapy manufacturer tested HEK293 cell banks by NGS (PathoQuest). NGS detected a novel parvovirus-like sequence not previously described. Follow-up testing (PCR, electron microscopy) confirmed non-infectious endogenous sequence. FDA accepted NGS data as part of safety package, avoiding additional in vivo testing.

7. Regional Outlook and Strategic Recommendations

• North America: Largest market (45% share, CAGR 6.5%). US (BioReliance, Charles River, Labcorp, KBI). Strong cell and gene therapy pipeline.
• Europe: Second-largest (30% share, CAGR 6.5%). France (Clean Cells, PathoQuest), UK (Intertek, Sartorius), Austria (ViruSure). Strong regulatory framework.
• Asia-Pacific: Fastest-growing region (CAGR 7.5%). China (Clean Biologics), India (Syngene). Cost-effective CRO services.
• Rest of World: Latin America, Middle East. Smaller but growing.

8. Conclusion

The adventitious agent detection market is positioned for strong growth through 2032, driven by cell and gene therapy expansion, regulatory requirements, and NGS adoption. Stakeholders—from biopharma companies to CROs—should prioritize NGS for broad-spectrum virus detection, in vitro methods for regulatory compliance, and mycoplasma PCR for rapid release testing. By enabling viral safety testing and biologics contamination control, adventitious agent detection is essential for patient safety and product quality.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Biologics Identity Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Biologics Identity Testing market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Biologics Identity Testing was estimated to be worth US$ 7391 million in 2025 and is projected to reach US$ 12750 million, growing at a CAGR of 8.2% from 2026 to 2032.
Biologics Identity Testing refers to the set of analytical methods and assays used to confirm the identity and authenticity of a biologic product (such as monoclonal antibodies, vaccines, cell or gene therapies, and recombinant proteins). The goal is to verify that the tested biologic is the correct product, with the expected molecular structure, sequence, and biological activity, and to distinguish it from other products, impurities, or contaminants.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096823/biologics-identity-testing

1. Industry Pain Points and the Shift Toward Comprehensive Identity Testing

Biologics—monoclonal antibodies, gene therapies, vaccines, and biosimilars—require rigorous identity confirmation to ensure product authenticity and patient safety. Unlike small-molecule drugs with simple chemical structures, biologics are complex macromolecules sensitive to manufacturing changes, potentially leading to product substitution, contamination, or loss of activity. Biologics identity testing addresses this through analytical methods (peptide mapping, mass spectrometry, ELISA, cell-based assays) that confirm molecular structure, sequence, and biological activity. For drug developers, CDMOs, and regulatory agencies, these tests are essential for regulatory compliance (FDA 21 CFR 610.14, ICH Q6B), product authentication, and distinguishing correct product from impurities or contaminants.

2. Market Size, Production Volume, and Growth Trajectory (2024–2032)

According to QYResearch, the global biologics identity testing market was valued at US$ 7.391 billion in 2025 and is projected to reach US$ 12.750 billion by 2032, growing at a CAGR of 8.2%. Market growth is driven by three factors: expanding biologics pipeline (over 10,000 biologics in development), increasing biosimilar development (requiring extensive identity comparability studies), and stringent regulatory requirements for cell and gene therapies.

3. Six-Month Industry Update (October 2025–March 2026)

Recent market intelligence reveals four notable developments:

• Biosimilar identity comparability: EMA and FDA accelerated biosimilar approvals (50+ approvals 2024-2025), requiring extensive analytical identity testing against reference products. Biosimilar segment grew 20% year-over-year.
• Gene therapy identity challenges: AAV capsid serotype confirmation and viral genome sequencing became critical for FDA IND submissions. Gene therapy identity testing grew 25% in 2025.
• High-throughput mass spectrometry: New LC-MS/MS platforms (Thermo Fisher, Charles River) reduced identity testing turnaround time from weeks to days.
• Chinese CRO expansion: Genscript Biotech and GL Biochem increased identity testing capacity by 30%, capturing Asia-Pacific market share.

4. Competitive Landscape and Key Suppliers

The market includes global CROs and specialized identity testing laboratories:

• Clean Cells (France), Charles River Laboratories (US), SGS SA (Switzerland), Eurofins Scientific (Luxembourg), BioAgilytix Labs (US), Genscript Biotech Corp. (China), AbbVie Inc. (US – internal testing), Rentschler Biopharma SE (Germany), Syngene International Ltd. (India), Thermo Fisher Scientific Inc. (US), GL Biochem Corp. (China), Abzena plc (UK).

Competition centers on three axes: analytical capabilities (mass spec, sequencing, immunoassays), regulatory expertise (FDA/EMA), and turnaround time.

5. Segment-by-Segment Analysis: Type and Application

By Service Type

• Method Development and Validation: (~45% of market). Developing identity tests for novel biologics (gene therapies, bispecific antibodies). Higher margin, longer timeline. Fastest-growing segment (CAGR 9%).
• Commercial Support Services: (~50% of market). Routine lot release testing for marketed biologics and biosimilars. High volume, recurring revenue.
• Others: Reference standard characterization, comparability studies. ~5% of market.

By End User

• Innovative Biologics Development: Largest segment (~50% of market). Novel mAbs, gene therapies, cell therapies.
• Biologics Development (biosimilars): (~30% of market). Extensive analytical similarity testing against reference products.
• Academic and Research Institutions: (~15% of market). Early-stage identity confirmation.
• Others: CDMOs, government labs. ~5% of market.

User case – Biosimilar identity comparability (mAb) : A biosimilar manufacturer outsourced identity testing to Charles River for a mAb candidate. Methods included peptide mapping (LC-MS), intact mass analysis, N-glycan profiling, and cell-based potency. All tests demonstrated analytical similarity to reference product (95-105% range), supporting FDA 351(k) submission.

6. Exclusive Insight: Identity Testing Methods Across Biologic Modalities

Technical challenge: Confirming identity of gene therapy products (AAV) where capsid serotype and genome sequence must both match. AAV identity testing requires:

• Capsid ELISA (serotype-specific antibodies)
• Genome sequencing (NGS or Sanger)
• ddPCR (confirm serotype-specific ITR sequences)
• Restriction mapping (confirm genome integrity)

User case – AAV serotype misidentification: A gene therapy developer misidentified AAV serotype (claimed AAV9, actually AAV2) based on limited testing. Comprehensive identity testing (capsid ELISA + genome sequencing) revealed error, preventing clinical trial failure. Correct serotype used for subsequent manufacturing, saving US$ 10 million+ in potential write-offs.

7. Regional Outlook and Strategic Recommendations

• North America: Largest market (45% share, CAGR 8%). US (Charles River, Thermo Fisher, BioAgilytix, AbbVie). Strong biologics pipeline and regulatory framework.
• Europe: Second-largest (30% share, CAGR 8%). France (Clean Cells), Switzerland (SGS), Luxembourg (Eurofins), Germany (Rentschler), UK (Abzena). Strong biosimilar development.
• Asia-Pacific: Fastest-growing region (CAGR 9.5%). China (Genscript, GL Biochem), India (Syngene). Cost-effective CRO services.
• Rest of World: Latin America, Middle East. Smaller but growing.

8. Conclusion

The biologics identity testing market is positioned for strong growth through 2032, driven by biologics pipeline expansion, biosimilar development, and regulatory requirements. Stakeholders—from pharmaceutical companies to CROs—should prioritize high-resolution mass spectrometry for peptide mapping, capsid/genome testing for gene therapies, and method development expertise for novel modalities. By enabling product authentication and regulatory compliance, biologics identity testing is essential for biologic drug development and patient safety.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “BioPharma Product Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global BioPharma Product Testing market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for BioPharma Product Testing was estimated to be worth US$ 9502 million in 2025 and is projected to reach US$ 19150 million, growing at a CAGR of 10.7% from 2026 to 2032.
BioPharma Product Testing refers to the set of laboratory analyses and quality assessments performed on biopharmaceutical products (such as monoclonal antibodies, recombinant proteins, vaccines, cell & gene therapies, and other biologics) to ensure that they are safe, effective, pure, and compliant with regulatory standards before being released to patients.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096605/biopharma-product-testing

1. Industry Pain Points and the Shift Toward Comprehensive Biologic Testing

Biopharmaceutical products—monoclonal antibodies, cell and gene therapies, vaccines, and biosimilars—require rigorous testing to ensure safety, efficacy, purity, and potency. Unlike small-molecule drugs, biologics are large, complex molecules produced in living systems, making them sensitive to manufacturing changes and susceptible to aggregation, degradation, and immunogenicity. BioPharma product testing addresses these challenges through specialized analytical methods (chemical analysis, bioanalysis, stability studies, and purity testing). For drug developers and contract testing organizations, these services are essential for regulatory compliance (FDA, EMA, ICH guidelines), quality control, and biologic safety assurance throughout development and commercialization.

2. Market Size, Production Volume, and Growth Trajectory (2024–2032)

According to QYResearch, the global BioPharma product testing market was valued at US$ 9.502 billion in 2025 and is projected to reach US$ 19.150 billion by 2032, growing at a CAGR of 10.7%. Market growth is driven by three factors: expanding biopharmaceutical pipeline (over 10,000 biologics in development), increasing adoption of biosimilars (requiring extensive comparability studies), and stringent regulatory requirements for cell and gene therapies.

3. Six-Month Industry Update (October 2025–March 2026)

Recent market intelligence reveals four notable developments:

• Cell and gene therapy testing demand: FDA approvals of Kymriah, Zolgensma, and others drove 25% increase in potency and safety testing for viral vectors and CAR-T products.
• Biosimilar comparability studies: European Medicines Agency (EMA) and FDA accelerated biosimilar approvals, requiring extensive analytical similarity testing. Biosimilar segment grew 20% year-over-year.
• Potency assay innovation: New cell-based potency assays (Eurofins, Charles River) for gene therapies reduced testing time from weeks to days.
• Chinese CRO expansion: Pharmaron and Frontage Laboratories increased capacity by 35%, capturing share in Asia-Pacific biologics outsourcing market.

4. Competitive Landscape and Key Suppliers

The market includes global CRO/CDMO giants and specialized bioanalytical laboratories:

• Eurofins Scientific (Luxembourg), SGS (Switzerland), Intertek (UK), Thermo Fisher Scientific (US), Charles River Laboratories (US), Labcorp (US), IQVIA (US), ICON plc (Ireland), Syneos Health (US), Pace Analytical (US), Almac Group (UK), BioAgilytix (US), Celerion (US), Frontage Laboratories (China/US), Pharmaron (China), CellCarta (Canada).

Competition centers on three axes: testing capacity (samples/year), regulatory expertise (FDA/EMA), and specialized capabilities (gene therapy, cell-based assays).

5. Segment-by-Segment Analysis: Type and Application

By Test Type

• Bioanalysis: Largest and fastest-growing segment (~55% of market). Pharmacokinetics (PK), immunogenicity (ADA), biomarker analysis, cell-based potency assays. CAGR 12%.
• Chemical Analysis: (~35% of market). Purity (HPLC, CE-SDS), aggregation (SEC), charge variants (iCIEF), peptide mapping (LC-MS).
• Others: Stability testing, sterility, mycoplasma, endotoxin. ~10% of market.

By End User

• Pharmaceutical Research Institute: Largest segment (~80% of market). Biotech and pharma companies outsourcing development and QC testing.
• Hospital: (~15% of market). Hospital laboratories for cell therapy release testing.
• Others: Government, academic. ~5% of market.

User case – Gene therapy potency assay development: A gene therapy company developing AAV-based treatment for hemophilia outsourced potency assay development to Charles River. A cell-based assay (transduction efficiency, functional protein expression) was developed and validated in 6 months, meeting FDA IND requirements. In-house development would have required 12+ months and US$ 2 million.

6. Exclusive Insight: Testing Complexity Across Biologic Modalities

User case – Biosimilar comparability: A biosimilar manufacturer tested its mAb candidate against reference product using Eurofins’ analytical similarity package (40 methods: primary structure, post-translational modifications, purity, potency). The 12-month study met FDA criteria, enabling submission and subsequent approval.

7. Regional Outlook and Strategic Recommendations

• North America: Largest market (45% share, CAGR 10.5%). US (Charles River, Labcorp, IQVIA, Thermo Fisher, Syneos, BioAgilytix, Celerion, Pace Analytical). Strong biologics pipeline and CDMO presence.
• Europe: Second-largest (30% share, CAGR 10%). Luxembourg (Eurofins), Switzerland (SGS), UK (Intertek, Almac), Ireland (ICON). Strong regulatory framework.
• Asia-Pacific: Fastest-growing region (CAGR 12.5%). China (Pharmaron, Frontage), India, Japan. Cost-effective CRO services.
• Rest of World: Latin America, Middle East. Smaller but growing.

8. Conclusion

The BioPharma product testing market is positioned for strong growth through 2032, driven by biologics pipeline expansion, biosimilar adoption, and cell/gene therapy approvals. Stakeholders—from pharmaceutical companies to CROs—should prioritize cell-based potency assays for gene therapies, analytical similarity packages for biosimilars, and regulatory expertise for global filings. By ensuring quality control and regulatory compliance, BioPharma product testing services are indispensable for biologic drug development and commercialization.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Protein Structure Prediction Tools – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Protein Structure Prediction Tools market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Protein Structure Prediction Tools was estimated to be worth US$ 425 million in 2025 and is projected to reach US$ 2405 million, growing at a CAGR of 28.5% from 2026 to 2032.
Protein structure prediction is the process of determining the three-dimensional structure of a protein from its amino acid sequence using computational methods. It’s a crucial field in bioinformatics, with applications in drug discovery, biotechnology, and understanding protein function.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096312/protein-structure-prediction-tools

1. Industry Pain Points and the Shift Toward AI-Powered Protein Folding

Experimental protein structure determination (X-ray crystallography, cryo-EM, NMR) is time-consuming (months to years), expensive (US$ 50,000-200,000 per structure), and technically challenging for many proteins. This limits drug discovery, protein engineering, and functional genomics. Protein structure prediction tools address this by using computational methods—homology modeling, ab initio modeling, and machine learning—to predict 3D structure from amino acid sequence in minutes to hours. The breakthrough of AlphaFold (Google DeepMind) and subsequent AI models has revolutionized the field, achieving experimental accuracy for hundreds of millions of proteins. For pharmaceutical companies, biotech firms, and research institutions, AI-powered prediction accelerates drug target identification, rational drug design, and protein engineering.

2. Market Size, Production Volume, and Hyper-Growth Trajectory (2024–2032)

According to QYResearch, the global protein structure prediction tools market was valued at US$ 425 million in 2025 and is projected to reach US$ 2.405 billion by 2032, growing at an exceptional CAGR of 28.5%. Market hyper-growth is driven by three factors: rapid adoption of AI/ML-based prediction tools (AlphaFold, RosettaFold, ESMFold), expansion of structural genomics and proteomics initiatives, and increasing demand for computational drug discovery (reducing time and cost of early-stage R&D).

3. Six-Month Industry Update (October 2025–March 2026)

Recent market intelligence reveals four explosive developments:

• AlphaFold Database expansion: DeepMind released predicted structures for over 200 million proteins (covering nearly all known organisms), democratizing structural biology. Database usage grew 50% year-over-year.
• NVIDIA BioNeMo launch: NVIDIA launched cloud-based generative AI platform for protein structure prediction and design, enabling biotech companies to fine-tune models on proprietary data. Platform adoption grew 80% in 2025.
• Rosetta Commons open-source growth: Community-driven Rosetta software suite added new deep learning modules (RoseTTAFold, ProteinMPNN), increasing academic and industry adoption by 35%.
• Schrödinger integration: Schrödinger integrated AlphaFold2 predictions into its drug discovery platform, reducing hit-to-lead timeline by 40%.

4. Competitive Landscape and Key Suppliers

The market includes AI research pioneers, cloud platform providers, and computational chemistry software vendors:

• Google DeepMind AlphaFold (UK – market leader, free access via AlphaFold Database), Meta AI (US – ESMFold, large language model for proteins), Rosetta Commons (US – open-source Rosetta suite, RoseTTAFold), NVIDIA BioNeMo (US – cloud platform, GPU-accelerated models), Schrödinger (US – computational chemistry software, integrated predictions), Helixon (US – deep learning for protein design).

Competition centers on three axes: prediction accuracy (RMSD vs. experimental), speed (seconds to minutes per protein), and scalability (millions of proteins).

5. Segment-by-Segment Analysis: Type and Application

By Prediction Method

• Machine Learning-Based Modeling: Dominant segment (~70% of market). AlphaFold, RosettaFold, ESMFold, and BioNeMo use deep learning (transformers, diffusion models). Fastest-growing (CAGR 32%), highest accuracy (1-2 Å RMSD for single-domain proteins).
• Homology Modeling: Traditional method using known template structures. Accuracy good (>30% sequence identity). Slower, requires template. Declining share (~20%).
• Ab Initio Modeling: Physics-based simulation (no template). Computationally expensive, lower accuracy. Niche (~10%).

By Application

• Drug Development: Largest segment (~60% of market). Target identification, binding site prediction, virtual screening, rational drug design. Fastest-growing segment (CAGR 30%).
• Biotechnology: (~30% of market). Protein engineering, enzyme design, antibody engineering, synthetic biology.
• Others: Basic research, agricultural biotechnology, industrial enzymes. ~10% of market.

User case – Drug target identification (Pfizer) : Pfizer used AlphaFold to predict structure of an undrugged G-protein coupled receptor (GPCR) target (1,000+ amino acids). Experimental structure determined by cryo-EM 18 months later confirmed predicted structure with 1.5 Å RMSD. Virtual screening against the predicted structure identified 3 lead compounds, saving 12 months of structural biology time and US$ 1.5 million in research costs.

6. Exclusive Insight: AI Model Architecture and Accuracy Comparison

Technical challenge: Predicting multi-domain protein interactions and conformational flexibility. Current AI models predict a single static structure, but many proteins change conformation upon binding. Solutions include:

• Ensemble prediction (multiple conformations)
• Flexible docking (allow backbone movement)
• Molecular dynamics (post-prediction simulation)
• Co-evolution analysis (predict interacting residues)

User case – Multi-domain protein prediction: A research team predicted structure of a multi-domain protein (1,200 residues, 4 domains) using AlphaFold2. The model correctly folded three domains but misoriented the fourth relative to the third. RoseTTAFold with domain parsing produced a more accurate inter-domain orientation (RMSD 3.2 Å vs. 5.5 Å). The team used a consensus approach (AlphaFold + Rosetta) for final model.

7. Regional Outlook and Strategic Recommendations

• North America: Largest market (45% share, CAGR 28%). US (Google DeepMind US office, Meta AI, NVIDIA, Schrödinger, Rosetta Commons). Strong pharmaceutical and biotech presence.
• Europe: Second-largest (25% share, CAGR 27%). UK (DeepMind, European Bioinformatics Institute). Strong academic and pharmaceutical research.
• Asia-Pacific: Fastest-growing region (CAGR 32%). China, Japan, South Korea. Increasing investment in AI for drug discovery.
• Rest of World: Smaller but growing.

8. Conclusion

The protein structure prediction tools market is positioned for explosive growth through 2032, driven by AI breakthroughs (AlphaFold, ESMFold, BioNeMo), drug discovery demand, and structural genomics initiatives. Stakeholders—from pharmaceutical companies to biotech startups—should prioritize ML-based modeling for accuracy and speed, cloud platforms (BioNeMo) for scalability, and integration with drug discovery workflows. By enabling AI-powered 3D modeling and deep learning for structure prediction, these tools are transforming computational biology and drug discovery.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp